Literature DB >> 15351160

Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study.

Gysèle S Bleumink1, Anneke M Knetsch, Miriam C J M Sturkenboom, Sabine M J M Straus, Albert Hofman, Jaap W Deckers, Jacqueline C M Witteman, Bruno H Ch Stricker.   

Abstract

AIMS: To determine the prevalence, incidence rate, lifetime risk and prognosis of heart failure. METHODS AND
RESULTS: The Rotterdam Study is a prospective population-based cohort study in 7983 participants aged > or =55. Heart failure was defined according to criteria of the European Society of Cardiology. Prevalence was higher in men and increased with age from 0.9% in subjects aged 55-64 to 17.4% in those aged > or =85. Incidence rate of heart failure was 14.4/1000 person-years (95% CI 13.4-15.5) and was higher in men (17.6/1000 man-years, 95% CI 15.8-19.5) than in women (12.5/1000 woman-years, 95% CI 11.3-13.8). Incidence rate increased with age from 1.4/1000 person-years in those aged 55-59 to 47.4/1000 person-years in those aged > or =90. Lifetime risk was 33% for men and 29% for women at the age of 55. Survival after incident heart failure was 86% at 30 days, 63% at 1 year, 51% at 2 years and 35% at 5 years of follow-up.
CONCLUSION: Prevalence and incidence rates of heart failure are high. In individuals aged 55, almost 1 in 3 will develop heart failure during their remaining lifespan. Heart failure continues to be a fatal disease, with only 35% surviving 5 years after the first diagnosis.

Entities:  

Mesh:

Year:  2004        PMID: 15351160     DOI: 10.1016/j.ehj.2004.06.038

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  285 in total

1.  Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study.

Authors:  Javed Butler; Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Kirsten Bibbins-Domingo; Samer S Najjar; Kim C Sutton-Tyrrell; Tamara B Harris; Stephen B Kritchevsky; Donald M Lloyd-Jones; Anne B Newman; Bruce M Psaty
Journal:  Heart       Date:  2011-06-02       Impact factor: 5.994

2.  Left ventricular epicardial admittance measurement for detection of acute LV dilation.

Authors:  John E Porterfield; Erik R Larson; James T Jenkins; Daniel Escobedo; Jonathan W Valvano; John A Pearce; Marc D Feldman
Journal:  J Appl Physiol (1985)       Date:  2010-12-09

3.  Country of birth and risk of hospitalization due to heart failure: a Swedish population-based cohort study.

Authors:  Yan Borné; Gunnar Engström; Birgitta Essén; Jan Sundquist; Bo Hedblad
Journal:  Eur J Epidemiol       Date:  2010-12-24       Impact factor: 8.082

4.  RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.

Authors:  Alberto J Alves; Nir Eynon; José Oliveira; Ehud Goldhammer
Journal:  World J Cardiol       Date:  2010-07-26

5.  Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.

Authors:  Ravi V Shah; Quynh A Truong; Hanna K Gaggin; Jens Pfannkuche; Oliver Hartmann; James L Januzzi
Journal:  Eur Heart J       Date:  2012-05-29       Impact factor: 29.983

6.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

Review 7.  Contemporary strategies in the diagnosis and management of heart failure.

Authors:  Shannon M Dunlay; Naveen L Pereira; Sudhir S Kushwaha
Journal:  Mayo Clin Proc       Date:  2014-03-29       Impact factor: 7.616

8.  Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.

Authors:  Thomas S G Sehested; Jenny Bjerre; Seul Ku; Andrew Chang; Alison Jahansouz; Douglas K Owens; Mark A Hlatky; Jeremy D Goldhaber-Fiebert
Journal:  JAMA Cardiol       Date:  2019-02-01       Impact factor: 14.676

Review 9.  Genetically changed mice with chronic deficiency or overexpression of the beta-adrenoceptors--what can we learn for the therapy of heart failure?

Authors:  Samuel Lee; Robert H G Schwinger; Klara Brixius
Journal:  Pflugers Arch       Date:  2007-09-14       Impact factor: 3.657

10.  Racial differences in incident heart failure among young adults.

Authors:  Kirsten Bibbins-Domingo; Mark J Pletcher; Feng Lin; Eric Vittinghoff; Julius M Gardin; Alexander Arynchyn; Cora E Lewis; O Dale Williams; Stephen B Hulley
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.